BEST-CLI International Collaborative: planning a better future for patients with chronic limb-threatening ischaemia globally.
作者信息
Farber Alik, Menard Matthew T, Bonaca Marc P, Bradbury Andrew, Conte Michael S, Debus E Sebastian, Eldrup Nikolaj, Goodney Philip, Gupta Prem C, Hinchliffe Robert J, Houlind Kim C, Kolh Philippe, Kum Steven Wei Cheong, Nordanstig Joakim, Parikh Sahil A, Patel Manesh R, Patrone Lorenzo, Sillesen Henrik, Strong Michael B, Varcoe Ramon L, Vega de Ceniga Melina, Venermo Maarit A, Rosenfield Kenneth
机构信息
Division of Vascular and Endovascular Surgery, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts, USA.
Division of Vascular and Endovascular Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
出版信息
Br J Surg. 2024 Jan 31;111(2). doi: 10.1093/bjs/znad413.
Abstract
摘要
相似文献
1
BEST-CLI International Collaborative: planning a better future for patients with chronic limb-threatening ischaemia globally.最佳慢性肢体威胁性缺血国际协作组：为全球慢性肢体威胁性缺血患者规划更美好的未来。
Br J Surg. 2024 Jan 31;111(2). doi: 10.1093/bjs/znad413.
2
Surgery or endovascular therapy for patients with chronic limb-threatening ischemia requiring infrapopliteal interventions.慢性肢体缺血高危患者的下肢动脉腔内治疗或手术治疗。
J Vasc Surg. 2024 Nov;80(5):1515-1524. doi: 10.1016/j.jvs.2024.05.049. Epub 2024 Jun 21.
3
Vein bypass first vs. best endovascular treatment first revascularisation strategy for chronic limb-threatening ischaemia due to infra-popliteal disease: the BASIL-2 RCT.静脉旁路术优先与最佳血管内治疗优先血运重建策略治疗下肢严重缺血性疾病：BASIL-2 RCT。
Health Technol Assess. 2024 Oct;28(65):1-72. doi: 10.3310/YTFV4524.
4
Critical limb ischemia.严重肢体缺血
Vasc Med. 2021 Apr;26(2):228-231. doi: 10.1177/1358863X20987611. Epub 2021 Feb 15.
5
A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial.对于需要进行 below-the-knee（小腿）、伴或不伴额外更近端 below-inguinal（腹股沟下）血运重建以恢复肢体灌注的慢性肢体威胁性缺血患者，静脉旁路优先与最佳血管内治疗优先再血管化策略的比较（BASIL-2）：一项开放标签、随机、多中心、3 期试验。
Lancet. 2023 May 27;401(10390):1798-1809. doi: 10.1016/S0140-6736(23)00462-2. Epub 2023 Apr 25.
6
Clinical trials in chronic limb-threatening ischaemia.慢性肢体威胁性缺血的临床试验。
Br J Surg. 2023 Mar 30;110(4):397-398. doi: 10.1093/bjs/znac465.
7
Revascularisation for Chronic Limb Threatening Ischaemia - The Need for Speed.慢性肢体威胁性缺血的血运重建——速度的必要性。
Eur J Vasc Endovasc Surg. 2023 Aug;66(2):158-159. doi: 10.1016/j.ejvs.2023.05.010. Epub 2023 May 13.
8
Outcomes of chronic limb-threatening ischemia revascularization in patients with chronic kidney disease in the BEST-CLI trial.BEST-CLI试验中慢性肾脏病患者慢性肢体威胁性缺血血运重建的结果
J Vasc Surg. 2025 Apr;81(4):945-956.e3. doi: 10.1016/j.jvs.2024.12.128. Epub 2025 Jan 23.
9
The impact of diabetes mellitus on the outcomes of revascularization for chronic limb-threatening ischemia in the BEST-CLI trial.糖尿病对BEST-CLI试验中慢性肢体威胁性缺血血管重建结局的影响。
J Vasc Surg. 2025 Feb;81(2):376-385.e3. doi: 10.1016/j.jvs.2024.09.026. Epub 2024 Sep 25.
10
Female patients have fewer limb amputations compared to male patients in the BEST-CLI trial.在BEST-CLI试验中，女性患者的肢体截肢情况比男性患者少。
J Vasc Surg. 2025 Feb;81(2):366-373.e1. doi: 10.1016/j.jvs.2024.09.031. Epub 2024 Oct 4.
引用本文的文献
1
Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes.STRIDE试验的设计与基线特征：评估司美格鲁肽在有症状外周动脉疾病和2型糖尿病患者中的疗效
Eur Heart J Cardiovasc Pharmacother. 2025 Jan 11;10(8):728-737. doi: 10.1093/ehjcvp/pvae071.
本文引用的文献
1
Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease.药物洗脱可吸收支架与血管成形术治疗下肢动脉疾病。
N Engl J Med. 2024 Jan 4;390(1):9-19. doi: 10.1056/NEJMoa2305637. Epub 2023 Oct 25.
2
Editor's Choice - Bypass versus Angioplasty for Severe Ischaemia of the Leg (BASIL) Prospective Cohort Study and the Generalisability of the BASIL-2 Randomised Controlled Trial.编辑推荐——腿部严重缺血的旁路手术与血管成形术（BASIL）前瞻性队列研究及BASIL-2随机对照试验的可推广性
Eur J Vasc Endovasc Surg. 2024 Jan;67(1):146-152. doi: 10.1016/j.ejvs.2023.09.041. Epub 2023 Sep 30.
3
Presence of Peripheral Artery Disease Is Associated With Increased Risk of Heart Failure Events: Insights From EMPEROR-Pooled.外周动脉疾病的存在与心力衰竭事件风险增加相关：来自EMPEROR汇总分析的见解。
Arterioscler Thromb Vasc Biol. 2023 Jul;43(7):1334-1337. doi: 10.1161/ATVBAHA.123.319156. Epub 2023 May 18.
4
A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial.对于需要进行 below-the-knee（小腿）、伴或不伴额外更近端 below-inguinal（腹股沟下）血运重建以恢复肢体灌注的慢性肢体威胁性缺血患者，静脉旁路优先与最佳血管内治疗优先再血管化策略的比较（BASIL-2）：一项开放标签、随机、多中心、3 期试验。
Lancet. 2023 May 27;401(10390):1798-1809. doi: 10.1016/S0140-6736(23)00462-2. Epub 2023 Apr 25.
5
Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia.慢性肢体威胁性缺血的手术或血管内治疗。
N Engl J Med. 2022 Dec 22;387(25):2305-2316. doi: 10.1056/NEJMoa2207899. Epub 2022 Nov 7.
6
Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.利拉鲁肽和司美格鲁肽对合并糖尿病和外周动脉疾病个体的心血管疗效。
Diabetes Obes Metab. 2022 Jul;24(7):1288-1299. doi: 10.1111/dom.14700. Epub 2022 Apr 11.
7
Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease.外周动脉疾病患者的血脂管理效果。
J Am Coll Cardiol. 2021 Jun 22;77(24):3016-3027. doi: 10.1016/j.jacc.2021.04.060.
8
Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety.利伐沙班和阿司匹林在下肢外周动脉疾病血管重建中的应用：氯吡格雷对疗效和安全性的影响。
Circulation. 2020 Dec 8;142(23):2219-2230. doi: 10.1161/CIRCULATIONAHA.120.050465. Epub 2020 Nov 3.
9
Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.达格列净与 DECLARE-TIMI 58 研究中伴或不伴外周动脉疾病患者的心脏、肾脏和肢体结局
Circulation. 2020 Aug 25;142(8):734-747. doi: 10.1161/CIRCULATIONAHA.119.044775. Epub 2020 Aug 3.
10
Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.急性冠状动脉综合征后外周动脉疾病和静脉血栓栓塞事件：脂蛋白(a)的作用和依洛尤单抗的修饰：ODYSSEY OUTCOMES 随机临床试验的预设分析。
Circulation. 2020 May 19;141(20):1608-1617. doi: 10.1161/CIRCULATIONAHA.120.046524. Epub 2020 Mar 29.
Zotero 插件